PJPatrick A. M. Jansen

Patrick A. M. Jansen

*This is an algorithmically generated author record based on publicly available information.

Patrick A. M. Jansen has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From prebiotics to engineered microbes: microbe-inspired treatments for atopic dermatitis

    by Noor E van Hout, Guillermo Nevot, Patrick A M Jansen, Ahmad A Mannan, Patrick L J M Zeeuwen, Dirk Jan Hijnen, Reiko J Tanaka, Marc Güell, Ellen H van Den Bogaard

    Atopic dermatitis (AD) is a common chronic inflammatory skin disease with diverse clinical and histological features. While primarily immune-mediated, genetic studies have also highlighted the role of epithelium-expressed gene abnormalities (e.g. FLG mutations) as a key factor. Approaches to treating AD are multifaceted, involving barrier restoration, local anti-inflammatory treatment and, if needed, systemic immunosuppressive therapy. Genetic variations in the stratum corneum and the immune system are linked to an imbalance between the host and its microbiota, known as dysbiosis. An impaired skin barrier and immune responses can alter the microbial composition, while the skin microbiota itself can influence skin immunity and barrier formation. A hallmark of AD is increased bacterial colonization with Staphylococcus aureus, which is found on lesional skin in > 90% of patients with AD. It contributes to disease severity by driving further breakdown of the skin barrier and immune stimulation. The most common treatments for S. aureus infections in AD are topical or systemic antibiotics. While these treatments are typically reserved for active infections, they are sometimes prescribed to patients with AD without a clear skin infection. These treatments can disrupt commensal skin and gut microbiota, which play a critical role in maintaining skin and gut health. In this review we describe various treatments that target the skin microbiome to reduce infection and inflammation in AD, including transplantation of microbiota, and the use of prebiotics, probiotics and postbiotics. In addition, we provide a perspective to engineer and harness bacteria of the skin microbiome as next-generation probiotics, also known as engineered live biotherapeutic products, using synthetic biology to create strains that can sense skin signals, such as immune signals, and environmental factors, and produce therapeutic treatments for AD on demand.


  • Open Access

    Investigating the Effect of Enzymatically-Derived Blackcurrant Extract on Skin Staphylococci Using an In Vitro Human Stratum Corneum Model

    by Marija Ćorović, Anja Petrov Ivanković, Ana Milivojević, Klaus Pfeffer, Bernhard Homey, Patrick A. M. Jansen, Patrick L. J. M. Zeeuwen, Ellen H. van Den Bogaard, Dejan Bezbradica

    Background/Objectives: Numerous intrinsic and extrinsic stressors can disrupt the balance of the skin microbiome, leading to the development of various skin diseases. It has been proven that coagulase-negative staphylococci (CoNS) are important commensals for maintaining skin microbiome homeostasis and fighting cutaneous pathogens such as Staphylococcus aureus (S. aureus). Here, we examined the influence of polyphenol-rich enzymatic blackcurrant extract (EBCE) on pathogenic coagulase-positive S. aureus strains and beneficial CoNS, like Staphylococcus epidermidis (S. epidermidis), to explore its potential for rebalancing the skin microbiota. Methods: The polyphenol profile of EBCE was determined by ultra-high-pressure liquid chromatography–tandem mass spectrometry. Microwell plate assays were employed to study the effect of EBCE on five S. aureus strains isolated from the skin of atopic dermatitis patients. An in vitro human stratum corneum model was used to test its effect on mixed bacterial cultures. Results: EBCE inhibited the growth of all tested S. aureus strains by 80–100% at the highest tested concentration after 7 h. No microbial growth was observed at the highest tested EBCE concentration using the stratum corneum model inoculated with one selected pathogen (S. aureus SA-DUS-017) and one commensal laboratory strain (S. epidermidis DSM 20044). The lowest tested concentration did not interfere with S. aureus growth but strongly stimulated the growth of S. epidermidis (~300-fold colony forming unit increase). In addition, low EBCE concentrations strongly stimulated CoNS growth in microbiome samples taken from the armpits of healthy volunteers that were spiked with S. aureus SA-DUS-017. Conclusions: These preclinical data support further testing of EBCE-enriched topical preparations as potential cutaneous prebiotics in human studies.


  • Open Access

    Investigations into the FLG Null Phenotype: Showcasing the Methodology for CRISPR/Cas9 Editing of Human Keratinocytes

    by Jos P.H. Smits, Noa J.M. van Den Brink, Luca D. Meesters, Hadia Hamdaoui, Hanna Niehues, Patrick A.M. Jansen, Ivonne M.J.J. van Vlijmen-Willems, Diana Rodijk-Olthuis, Céline Evrard, Yves Poumay, et al.


  • ESDR172 - CYSRT1: an antimicrobial epidermal protein that interacts with late cornified envelope (LCE) proteins

    by Hanna Niehues, Gijs Rikken, Ferry Kersten, Jorine Eeftens, Merel Oortveld, Danique van der Krieken, Patrick Jansen, Ivonne van Vlijmen-Willems, Jos Smits, Noa van Den Brink, et al.

    Late cornified envelope (LCE) proteins are small cationic epidermal proteins with antimicrobial properties, and the combined deletion of LCE3B an | POSTER

  • Open Access

    Antimicrobial Late Cornified Envelope Proteins: The Psoriasis Risk Factor Deletion of LCE3B/C Genes Affects Microbiota Composition

    by Hanna Niehues, Danique A. van der Krieken, Thomas H.A. Ederveen, Patrick A.M. Jansen, Laura van Niftrik, Rob Mesman, Mihai G. Netea, Jos P.H. Smits, Joost Schalkwijk, Ellen H. van Den Bogaard, et al.


  • Antimalarial pantothenamide metabolites target acetyl–coenzyme A biosynthesis in Plasmodium falciparum

    by Joost Schalkwijk, Erik L. Allman, Patrick A. M. Jansen, Laura E. de Vries, Julie M. J. Verhoef, Suzanne Jackowski, Peter N. M. Botman, Christien A. Beuckens-Schortinghuis, Karin M. J. Koolen, Judith M. Bolscher, et al.

    Pantothenamides form antimetabolites that interfere with acetyl-CoA metabolism in the human malaria parasite Plasmodium falciparum.


  • Open Access

    Stable pantothenamide bioisosteres: novel antibiotics for Gram-positive bacteria

    by Patrick A. M. Jansen, Danique A. van der Krieken, Peter N. M. Botman, Richard H. Blaauw, Lorenzo Cavina, Eline M. Raaijmakers, Erik de Heuvel, Julia Sandrock, Lian J. Pennings, Pedro H. H. Hermkens, et al.

    The emergence of multidrug resistant bacteria has prioritized the development of new antibiotics. N-substituted pantothenamides, analogs of the natural compound pantetheine, were reported to target bacterial coenzyme A biosynthesis, but these compounds have never reached the clinic due to their instability in biological fluids. Plasma-stable pantothenamide analogs could overcome these issues. We first synthesized a number of bioisosteres of the prototypic pantothenamide N7-Pan. A compound with an inverted amide bond (CXP18.6-012) was found to provide plasma-stability with minimal loss of activity compared to the parent compound N7-Pan. Next, we synthesized inverted pantothenamides with a large variety of side chains. Among these we identified a number of novel stable inverted pantothenamides with selective activity against Gram-positive bacteria such as staphylococci and streptococci, at low micromolar concentrations. These data provide future direction for the development of pantothenamides with clinical potential.


  • Open Access

    Antimalarial pantothenamide metabolites target acetyl-CoA synthesis in Plasmodium falciparum

    by Joost Schalkwijk, Erik L. Allman, Patrick A.M. Jansen, Laura E. de Vries, Suzanne Jackowski, Peter N. M. Botman, Christien A. Beuckens-Schortinghuis, Karin M.J. Koolen, Judith M Bolscher, Martijn W. Vos, et al.

    Malaria eradication is critically dependent on novel drugs that target resistant Plasmodium parasites and block transmission of the disease. Here we report the discovery of potent pantothenamide bioisosteres that are active against blood-stage P. falciparum and also block onward mosquito transmission. These compounds are resistant to degradation by serum pantetheinases, show favorable pharmacokinetic properties and clear parasites in a humanized rodent infection model. Metabolomics revealed that CoA biosynthetic enzymes convert pantothenamides into drug-conjugates that interfere with parasite acetyl-CoA anabolism. In vitro generated resistant parasites showed mutations in acetyl-CoA synthetase and acyl-CoA synthetase 11, confirming the key roles of these enzymes in the sensitivity to pantothenamides. These new pantothenamides provide a promising class of antimalarial drugs with a unique mode of action. One sentence summary: Pantothenamides form antimetabolites that interfere with acetyl-CoA metabolism in the human malaria parasite Plasmodium falciparum


  • Open Access

    Novel pantothenate derivatives for anti-malarial chemotherapy

    by Helmi E Pett, Patrick Am Jansen, Pedro Hh Hermkens, Peter Nm Botman, Christien A Beuckens-Schortinghuis, Richard H Blaauw, Wouter Graumans, Marga van de Vegte-Bolmer, Karin Mj Koolen, Floris Pjt Rutjes, et al.

    A number of synthetic pantothenate derivatives, such as pantothenamides, are known to inhibit the growth of the human malaria parasite Plasmodium falciparum, by interfering with the parasite Coenzyme A (CoA) biosynthetic pathway. The clinical use of pantothenamides is limited by their sensitivity to breakdown by ubiquitous human pantetheinases of the vanin family. A number of pantothenate derivatives (pantothenones) with potent and specific inhibitory activity against mammalian vanins were tested in a proliferation assay of asexual P. falciparum blood stages alone, and in combination with pantothenamides. The vanin inhibitors were found to protect pantothenamides against breakdown by plasma vanins, thereby preserving the in vitro anti-malarial activity. Moreover, some of the vanin inhibitors showed in vitro anti-malarial activity in the low micromolar range. The most potent antimalarial in this series of compounds (RR8), was found to compete with pantothenate in a combination proliferation assay. No correlation, however, was found between anti-vanin and anti-malarial activity, nor was pantetheinase activity detected in P. falciparum extracts. Growth inhibition is most likely due to competition with pantothenate, rather than pantetheinase inhibition. As vanin inhibitors of the pantothenone class are stable in biological fluids and are non-toxic to mammalian cells, they may represent novel pantothenate-based anti-malarials, either on their own or in combination with pantothenamides.